Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

PURPOSE: Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (PD-1/L1) therapy. Enfortumab vedotin is an antibody–dr...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2019
Onderwerpen:
RAPID COMMUNICATION
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784850/
https://ncbi.nlm.nih.gov/pubmed/31356140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01140
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items